CSL Biotherapies Starts Shipment of Seasonal Influenza Vaccine for the 2009-2010 Flu Season.

U.S. licensed manufacturer on track to deliver all seasonal flu vaccine, including its thimerosal-free formulation, before the end of September

KING OF PRUSSIA, Pa. -- CSL Biotherapies, a subsidiary of one of the world's leading manufacturers of thimerosal-free seasonal influenza vaccine, announced today that it has begun shipment of its seasonal influenza virus vaccine to a national network of U.S. distributors for the 2009-2010 season. CSL Biotherapies plans to deliver more than eight million doses of the vaccine, the majority of which will be in single-dose, thimerosal-free, pre-filled syringes.

CSL Biotherapies' seasonal flu vaccine is indicated for the active immunization of persons age 18 years and older against influenza disease (commonly referred to as the "flu") caused by influenza virus subtypes A and type B present in the vaccine.

"CSL Biotherapies' early delivery of seasonal influenza vaccine to the U.S. clearly demonstrates our ability to rapidly optimize vaccine production in order to meet evolving public health needs," said Paul Perreault, President of CSL Biotherapies. "Working with the U.S. government, we are also moving quickly to develop a vaccine to address the H1N1 pandemic. Together, these efforts illustrate the expertise in influenza vaccine development and manufacturing that CSL has so successfully accumulated over the past 40 years."

CSL Limited, the parent company of CSL Biotherapies, is the first vaccine manufacturer to initiate human clinical trials of the H1N1 influenza vaccine. First administration in healthy volunteers of CSL's experimental H1N1 pandemic vaccine began on July 22 , 2009 in Australia. U.S. clinical studies are expected to commence in mid-August.

About CSL Biotherapies

The U.S. headquarters of CSL Biotherapies are located in King of Prussia, Pa. Its parent company, CSL Limited, in Melbourne, Australia, operates one of the world's largest influenza vaccine facilities for global markets. CSL Biotherapies, which shares its U.S. headquarters with its sister company, CSL Behring, is commercializing influenza vaccine products globally. At CSL Biotherapies, delivering vaccines is our mission, protecting lives our passion. The CSL Group, which includes CSL Biotherapies, CSL Research & Development, CSL Bioplasma, and CSL Behring, has more than 10,000 employees and operates in 27 countries worldwide. For more information, visit us at www.cslbiotherapies-us.com, or call 1-888-435-8633.